# Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia

> **NCT01513603** · PHASE2 · UNKNOWN · sponsor: **New York Medical College** · enrollment: 50 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Lymphoblastic Lymphoma
- Burkitts Leukemia/Lymphoma
- Chronic Myelogenous Leukemia

## Interventions

- **DRUG:** CLAG-M
- **DRUG:** CLAG-M

## Key facts

- **NCT ID:** NCT01513603
- **Lead sponsor:** New York Medical College
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-01
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2012-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01513603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01513603, "Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01513603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*